



The Effect of Intraoperative Cerebral Oximetry Monitoring on Postoperative Cognitive Dysfunction and ICU Stay in Adult Patients Undergoing Cardiac Surgery: An Updated Systematic Review and Meta-Analysis

Li-Juan Tian, Su Yuan, Cheng-Hui Zhou* and Fu-Xia Yan*

Department of Anesthesiology, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

OPEN ACCESS

Edited by:

Hendrik Tevaearai Stahel, Bern University Hospital, Switzerland

Reviewed by:

Markus Mach, Medical University of Vienna, Austria Dimitrios Iliopoulos, Hygeia Hospital, Greece

*Correspondence:

Cheng-Hui Zhou chenghuizhou@yahoo.com Fu-Xia Yan yanfuxia@sina.com

Specialty section:

This article was submitted to Heart Surgery, a section of the journal Frontiers in Cardiovascular Medicine

> Received: 13 November 2021 Accepted: 31 December 2021 Published: 01 February 2022

Citation:

Tian L-J, Yuan S, Zhou C-H and Yan F-X (2022) The Effect of Intraoperative Cerebral Oximetry Monitoring on Postoperative Cognitive Dysfunction and ICU Stay in Adult Patients Undergoing Cardiac Surgery: An Updated Systematic Review and Meta-Analysis. Front. Cardiovasc. Med. 8:814313. doi: 10.3389/fcvm.2021.814313 **Aim:** Determining whether intraoperative cerebral oximetry monitoring-guided intervention reduces the risk of postoperative cognitive dysfunction remains controversial. The objective of this study was to conduct an up-to-date meta-analysis to comprehensively assess the effects of regional cerebral oxygen saturation (rSO₂) monitoring-guided intervention on cognitive outcomes after cardiac surgery.

Methods: PubMed, EMBASE, Ovid, and Cochrane Library databases were systematically searched using the related keywords for cardiac surgical randomized-controlled trials (RCTs) published from their inception to July 31, 2021. The primary outcome was postoperative delirium (POD). The secondary outcomes were postoperative cognitive decline (POCD) and other major postoperative outcomes. The odds ratio (OR) or weighted mean differences (WMDs) with 95% confidence interval (CI) were used to pool the data. The random-effect model was used for the potential clinical inconsistency. We performed meta-regression and subgroup analyses to assess the possible influence of rSO₂ monitoring-guided intervention on clinical outcomes.

Results: In total, 12 RCTs with 1,868 cardiac surgical patients were included. Compared with controls, the incidences of POD (n = 6 trials; OR, 0.28; 95% CI, 0.09–0.84; p = 0.02; $l^2 = 81\%$) and POCD (n = 5 trials; OR, 0.38; 95% CI, 0.16–0.93; p = 0.03; $l^2 = 78\%$) were significantly lower in the intervention group. Cerebral oximetry desaturation also showed a positive association with the incidence of POD (n = 5 trials; OR, 2.02; 95% CI, 1.25–3.24; p = 0.004; $l^2 = 81\%$). The duration of intensive care unit (ICU) stay was markedly shorter in the intervention group than in the control group (n = 10 trials; WMD, -0.22 days; 95% CI, -0.44 to -0.00; p = 0.05; $l^2 = 74\%$). Univariate meta-regression analyses showed that the major sources of heterogeneity were age (p = 0.03), body mass index (BMI, p = 0.05), and the proportion of congenital heart disease (CHD, p = 0.02) for POD, age (p = 0.04) for POCD, diabetes mellitus (DM, p = 0.07), cerebrovascular accident (CVA,

p = 0.02), and chronic obstructive pulmonary disease (COPD, p = 0.09) for ICU stay. Subsequent subgroup analyses also confirmed these results.

Conclusion: Available evidence from the present study suggests that an intraoperative cerebral oximetry desaturation is associated with an increased POD risk, and the rSO₂ monitoring-guided intervention is correlated with a lower risk of POD and POCD, and a shorter ICU stay in adults undergoing cardiac surgery. These clinical benefits may be limited in patients with older age, diabetes status, high BMI, non-CHD, non-COPD, or a previous cardiovascular accident.

Systematic Review Registration: [PROSPREO], identifier: [CRD42021252654].

Keywords: cardiac surgery, cardiopulmonary bypass, postoperative delirium, regional cerebral oxygen saturation, postoperative cognitive decline

INTRODUCTION

Transient cognitive dysfunction following cardiac surgery with cardiopulmonary bypass (CPB) is a common and clinically important complication (1). Postoperative delirium (POD) is the most severe presentation of neurocognitive disorders with a rate of up to 50% of cardiac surgical patients (2), which contributes to a prolonged hospital stay, long-term cognitive impairment, and increased morbidity and mortality (1, 3-7). Some previous studies showed that patients were susceptible to neurocognitive disorders from hypoperfusion and microemboli resulting in impaired cerebrovascular autoregulation during cardiac surgery undergoing CPB (8). In a cohort study concerning cardiac surgery, intraoperative post-ischemia cerebral hyperoxygenation has been shown to be strongly associated with an increased risk of postoperative cognitive dysfunction (9). Near-infrared spectroscopy (NIRS) possesses the potential of non-invasively evaluating the oxygen supply/demand balance in frontal brain tissue and providing real-time regional cerebral oxygen saturation (rSO₂) even during non-pulsatile perfusion, and intraoperative decreased rSO₂ may indicate a clinically relevant association with cognitive dysfunction (10-12). Additionally, there are very few literature studies supporting that anesthetic practice based on optimizing cerebral oxygenation during cardiac surgery leads to improved postoperative outcomes (13, 14). However, this conclusion was still controversial as some recently randomized-controlled trials (RCTs) have demonstrated that NIRS-guided intervention has no effect on the reduction of neurocognitive disorders after cardiac and non-cardiac surgeries (15, 16). Two prospective randomized studies, including highrisk patients conducted by Lei et al. and Deschamps et al., found that NIRS-guided intervention could attenuate the decreases of rSO₂ in cardiac surgery but did not affect the incidence of POD (17, 18).

Therefore, the effect of intraoperative NIRS-guided intervention on postoperative cognitive dysfunction in cardiac surgical patients with CPB remains unclear. An up-to-date systematic review and meta-analysis aim to comprehensively evaluate the effects of intraoperative anesthetic practice based on cerebral oximetry monitoring on delirium and cognitive outcomes after cardiac surgery.

METHODS

This study followed the methodology outlined in the Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (19). We explained it in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA) statement. This protocol has been registered on the International Prospective Systematic Reviews Registry database (PROSPERO 2021: CRD42021252654).

Search Strategy

PubMed, EMBASE, Ovid, and Cochrane Library databases were searched for English articles published from their inception to July 31, 2021, for RCTs evaluating the effects of intraoperative anesthetic practice followed cerebral oximetry monitoring on post-cardiac surgery cognitive outcomes. The related ongoing or completed studies on ClinicalTrials.gov were also searched, and the references of the identified studies were also reviewed to identify further relevant studies. The related searching words were as follows: (Postoperative delirium) OR (Postoperative Cognitive Dysfunctions) AND [(cardiac surgery) OR (cardiopulmonary bypass) OR (coronary artery bypass surgery) OR (valve surgery) OR (aortic surgery) OR (congenital heart disease)] AND (intraoperative cerebral oximetry) AND (randomized controlled trial OR controlled clinical trial OR randomly OR trial) in the title/abstract. In addition, we manually searched the references of the identified studies.

Selection Criteria

The study selection criteria were as follows: (1) Population: populations of interest were adult patients undergoing cardiac surgery. Studies concerning children, infants, or newborns were excluded. (2) Intervention: The intervention group was NIRS-guided therapy. (3) Comparator: The intervention group vs. the control group. (4) Outcome: The incidence of POD. (5) Study design: Only included RCTs to ensure that the combined results

were of good quality, and excluded the studies that could not provide effective analysis data.

Interventions

Thresholds for intervention were generally below 70–90% baseline rSO_2 or below 50–60% absolute rSO_2 . Intraoperative cerebral oximetry-guided therapy was considered as the primary intervention and was triggered by the evidence of cerebral oxygen desaturation. Specific interventions included the fluid supplement and/or vasoactive drugs for hypotension, changes in ventilatory parameters to optimize the partial pressure arterial oxygen and carbon dioxide, or blood transfusion.

Outcomes and Definitions

The primary outcome was the incidence of POD as defined in the individual studies. The secondary outcomes were postoperative cognitive decline (POCD) and intensive care unit (ICU) stay. Additional outcomes included mechanical ventilation duration, hospital length of stay (LOS), as well as the incidence of myocardial infarction (MI), acute kidney injury (AKI), surgical site infection, cerebrovascular accident (CVA), and hospital mortality.

Data Collection and Quality Assessment


Two researchers (LJT and CHZ) independently extracted the following study design and patient characteristics:

research title, author's name, the year of publication, the journal of included studies, research area (hospital or research institute), total number of patients, the number of patients in the two groups, gender, age, the type of surgical procedure, and the data regarding outcomes of interest in both groups.

The two researchers evaluated the quality of the included studies in accordance with the quality assessment section of the Cochrane handbook for systematic reviews of interventions 6.0. Two researchers also assessed selection bias, blind bias, incomplete outcome data bias, selective reporting bias, and other biases for each included study (20). Disagreements were resolved through a discussion during the process of data abstraction. The quality of the study was categorized as low-, medium-, or high-risk accordingly. In addition, the baseline characteristics and comorbidity were compared between the intervention and control groups in each study for patients.

Statistical Analysis

All the data were analyzed by Review Manager 5.4 (Cochrane Collaboration, Oxford, UK), Stata 12.0 (Stata Corporation, College Station, TX, USA), and Trial Sequential Analysis 0.9 Beta (Copenhagen Trial Unit, Copenhagen, Denmark). The odds ratios (ORs) with 95% confidence intervals (CIs) were estimated for dichotomous data, and weighted mean differences (WMDs)



with 95% CIs for continuous data, respectively. In addition, we converted the data expressed as the median and interquartile range (IQR), to mean and SD by the formulas of Luo and Wan (21). The random-effect model was used to pool the data for the consideration of methodological and clinical heterogeneity. Q-test (p < 0.1 denoted statistically significant heterogeneity) and I^2 statistics ($I^2 > 50\%$ was considered as the presence of significant heterogeneity) were used to evaluate the heterogeneity of this study. Meta-regression (p < 0.1) and subgroup analyses were conducted for positive results to explore the potential sources of heterogeneity between rSO₂ monitoring-guided intervention and clinical outcomes. To reduce the possibility of overfitting in the regression model, at least four studies or substudies were set for the identification of every one influential factor (22). Publication

bias was evaluated with the Egger's and Begg's tests (23). We performed the trial sequential analyses (TSAs) of POD, POCD, and ICU stay based on the data from our pooled analysis (OR and the incidence of POD or POCD; WMD and variance) to calculate the required sample size for the statistical power. P < 0.05 was set as statistically significant.

RESULTS

Literature Search, Study Characteristics, and Quality Assessment

As depicted in the flow chart (**Figure 1**), our initial search yielded 2,702 records. A total of 2,662 trials were excluded by being

TABLE 1 | Baseline characteristics of included studies for meta-analysis.

References	Sample	size	Age	(y)	Sex (M	/F)	Surgery	Intervention	Outcome	
	Intervention	Control	Intervention	Control	Intervention	Control				
Uysal et al. (16)	59	66	57 ± 11	58 ± 12	40/19	46/20	Cardiac surgery	rSO ₂ below 60% for 1 min or longer	POD, ICU stay, hospital LOS, transfusion requirement and SOFA on ICU admission	
Deschamps et al. (17)	102	99	69 ± 12.6	72 ± 9.4	74/28	71/28	Cardiac surgery	rSO_2 decreased by 10% of baseline for a duration exceeding 15 s	POD, ICU stay, hospital LOS, MI, transfusion requirement, infection and MOMM	
Lei et al. (18)	123	126	74.2 ± 6.5	72.9 ± 6.3	88/35	88/38	Cardiac surgery	rSO_2 below 75% of the baseline value for 1 min or longer	POD, ICU stay, hospital LOS, MI, transfusion requirement, infection and mortality	
Murkin et al. (24)	100	100	61.8 ± 9.3	61.8 ± 10.3	87/13	88/12	CABG	rSO ₂ values at or above 75% baseline value	ICU stay, hospital LOS, wound infection and MI	
Slater et al. (25)	125	115	64.33 ± 10.2	65.19 ± 9.7	104/21	97/22	CABG	rSO ₂ drop more than 20% baseline value	POCD and hospital LOS	
Vretzakis et al. (26)	75	75	67.3 ± 8.5	65.9 ± 9.5	63/12	60/15	Cardiac surgery	$rSO_2 < 60\%$ or decreased by 20% of baseline	ICU stay, hospital LOS and transfusion requirement	
Deschamps et al. (27)	23	25	71.1 ± 7.9	70.2 ± 9.2	19/4	14/11	High-risk cardiac surgery	rSO ₂ decreased by 20% of baseline for a duration exceeding 15 sec	ICU stay, hospital LOS, and transfusion requirement	
Mohandas et al. (28)	50	50	34.6 ± 16.3	38.1 ± 15.8	30/20	28/22	Open heart surgery	rSO ₂ below 85% of the baseline or below 50% for 1 min or longer	POCD (postoperative 1 week and 3 months)	
Colak et al. (29)	94	96	61.9 ± 7.1	63.4 ± 8.8	75/19	73/23	CABG	rSO_2 below 80% of the baseline or below 50%	POD POCD, ICU stay, hospital LOS, MI, transfusion requirement and infection rate	
Kara et al. (30)	43	36	59.1 ± 9.4	61.2 ± 10.3	33/10	29/7	CABG	rSO ₂ below 80% of the baseline	POCD, ICU stay and hospital LOS	
Rogers et al. (31)	98	106	65.9 ± 22.7	70 ± 19.7	66/32	74/32	Open valve or combined CABG and valve surgery	rSO_2 below 70% of the baseline or below 50%	ICU stay, hospital LOS, MI, transfusion requirement, infection and mortality	
Kunst et al. (32)	42	40	71.6 ± 5	72 ± 4.3	33/9	34/6	CABG	rSO ₂ below 85% of the baseline or below 50%	POD and POCD, ICU stay and hospital LOS	

CABG, coronary artery bypass graft; POD, postoperative delirium; POCD, postoperative cognitive decline; rSO₂, regional cerebral oxygen saturations; MI, myocardial infarction; ICU, intensive care unit; LOS, length of stay; SOFA, sequential Organ failure assessment; MOMM, major organ morbidity and mortality.

References	Age (Year)	Male (%)	BMI	Pre-MI (%)	DM (%)	HT (%)	CVA (%)	COPD (%)	CRF (%)	CPB duration (min)	Euroscore	Baseline LVEF (%)	CABG (%)	CHD (%)	Valve surgery (%)	Complex surgery (%)
Uysal et al. (16)	57.5	68.8	26.8	NA	NA	NA	NA	NA	NA	131.1	2.5	60.0	5.6	0	67.2	27.2
Deschamps et al. (17)	71.0	72.1	NA	4.5	29.4	79.6	NA	9.9	13.9	135.9	5.3	NA	NA	0	28.2	70.1
Lei et al. (18)	73.5	70.7	28.1	12.4	27.7	76.7	14.5	12.9	NA	111.0	NA	NA	55.8	0	NA	43.8
Murkin et al. (24)	61.8	87.5	29.6	5	28.5	NA	7.0	17.5	8.5	88.2	NA	NA	100	0	0	0
Slater et al. (25)	64.7	83.5	NA	16.0	32.9	78.3	7.5	5.6	4.4	65.6	NA	51.1	100	0	0	0
Vretzakis et al. (26)	66.6	82.0	27.8	54.7	24	80.6	NA	21.3	NA	91.3	NA	47.8	80.7	1.3	10.0	8.0
Deschamps et al. (27)	70.6	68.8	NA	NA	NA	NA	NA	NA	NA	116.6	NA	56.3	19.0	0	23.8	50.2
Mohandas et al. (28)	36.3	58.0	20.7	NA	NA	NA	NA	NA	NA	88.7	NA	NA	0	20.0	74.0	6.0
Colak et al. (29)	62.7	78.0	NA	11.6	33.7	90.5	NA	NA	1.6	90.0	2.3	56	100	0	0	0
Kara et al. (30)	60.1	78.5	NA	NA	30.4	74.7	12.7	15.2	1.3	78.1	NA	54.0	100	0	0	0
Rogers et al. (31)	68.0	69.0	27.6	10.0	9.0	NA	8.0	NA	NA	108.8	5.0	NA	0	0	77.0	23.0
Kunst et al. (32)	71.8	81.7	26.7	NA	31.7	92.7	14.6	11.0	NA	81.1	4.4	NA	100	0	0	0

TABLE 2 | Baseline characteristics, medical conditions, and perioperative data of included studies for meta-analysis.

BMI, body mass index; MI, myocardial infarction; DM, diabetes mellitus; HT, hypertension; CVA, cerebrovascular accident; COPD, chronic obstructive pulmonary disease; CRF, chronic renal failure CPB, cardiopulmonary bypass; Euroscore, European system for cardiac operative risk evaluation; EF, ejection fraction; CABG, coronary artery bypass graft; CHD, congenital heart disease; NA, not available.

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias	
Colak, 2015	•	•	•	•	٠	•	•	
Deschamps, 2013	?	?	•	•	•	?	•	
Deschamps, 2016	•	•	•	?	•	•	•	
Kara, 2015	•	•	•	•	•	•	•	
Kunst, 2020	•	•	•	•	•	•	•	
Lei, 2017	•	•	?	?	٠	•	•	
Mohandas, 2013	•	?	?	?	•	?	•	
Murkin, 2007	•	•	?	•	•	•	•	
Rogers, 2017	•	•	•	•	•	•	•	
Slater, 2009	•	?	?	?	•	•	•	
Uysal, 2020	•	•	?	?	•	•	•	
Vretzakis, 2013	•	•	•	•	•	?	?	




FIGURE 3 | Risk of bias graph of review authors' judgments about each risk of bias item presented as the percentage across all included studies.

duplicated and reviewing the titles and abstracts. Twenty-four of the trials were excluded for a non-RCT design. Seven trials were terminated without neurologic outcomes. One trial was excluded due to the exploration of the relationship between postoperative cerebral oxygen and delirium. In total, 12 RCTs with 1,868 adult cardiac surgical patients were included in this meta-analysis (16–18, 24–32).

Study Patient and Intervention Characteristics

The study characteristics are presented in **Tables 1**, **2**. The screening included 1,868 patients undergoing cardiac surgery (on-pump coronary artery bypass graft (CABG), valve surgery, and CABG combined valve surgery) for meta-analysis, including 934 patients allocated into the intervention group and 934 in the control group. The definition criteria of cerebral oximetry desaturation in each study vary from below 70–90% of baseline rSO₂ or below 50–60% absolute rSO₂. The interventions to correct cerebral oxygen desaturation included the optimization of mechanical ventilation strategy, vasopressor delivery, fluid administration, and blood transfusion.

Quality Assessment

Six studies with an unclear risk of bias were due to the unclear blinding assessments or participants and personnel (16, 17, 26–28). Two, trials did not describe the study design in detail and were not clear about the selective reporting bias (24, 25), almost all the included RCTs were assessed as low bias risk, indicating that they were of good quality (**Figures 2**, **3**).

Primary Outcomes

Six RCTs with 826 patients were assessed for POD with an overall incidence of 18.0% (intervention, 11.9%; control, 23.8%). There was a significant decrease in the incidence of POD in the

intervention group relative to the control group (**Figure 4A**; OR, 0.28; 95% CI, 0.09–0.84; p = 0.02; $I^2 = 81\%$).

There was an increased occurrence of POD with cerebral oximetry desaturation defined by both relative (below 70–90% baseline rSO₂) or absolute (below 50–60% absolute rSO₂) thresholds (**Figure 4B**; OR, 2.02; 95% CI, 1.25–3.24; p = 0.004; $I^2 = 81\%$) in five RCTs including 859 patients undergoing cardiac surgery.

Secondary Outcomes

The POCD was reported in 858 study participants, and the overall incidence was 31.1% (intervention, 114/435; control, 170/423). POCD was reported in five trials, there was a significant reduction in POCD after cardiac surgery in the intervention group (**Figure 4C**; OR, 0.38; 95% CI, 0.16–0.93; p = 0.03; $I^2 = 78\%$).

The mechanical ventilation duration was explored in eight trials with 1,263 patients without a statistically significant difference between the two groups (**Figure 5A**; WMD, -0.27 h; 95% CI, -1.52-0.99; p = 0.68; $I^2 = 63\%$). The ICU stay was examined in 10 trials with 1,459 patients. The lengths of ICU stay were less in the intervention group with a marginal statistical significance (**Figure 5B**; WMD, -0.22 days; 95% CI, -0.44 to -0.00; p = 0.05; $I^2 = 74\%$). The pooled analysis found no significant difference in hospital LOS between the groups (**Figure 5C**; WMD, -0.02 days; 95% CI, -0.73-0.70; p = 0.96; $I^2 = 88\%$).

There were no significant differences in the incidence of MI (**Figure 6A**; OR, 0.90; 95% CI, 0.43–1.92; p = 0.79; $I^2 = 0\%$), AKI (**Figure 6B**; OR, 0.94; 95% CI, 0.57–1.55; p = 0.81; $I^2 = 0\%$), surgical site infection (**Figure 6C**; OR, 0.86; 95% CI, 0.58–1.28; p = 0.46; $I^2 = 0\%$), CVA (**Figure 6D**; OR, 1.27; 95% CI, 0.51–3.17; p = 0.60; $I^2 = 0\%$), and hospital mortality (**Figure 6E**; OR, 0.81; 95% CI, 0.37–1.78; p = 0.60; $I^2 = 0\%$) between the two groups.

	Study or Subgroup	Interve		Cont		Moight	Odds Ratio	Odds Ratio M-H. Random, 95% Cl
	Mohandas, 2013	2	50	34	50		M-H, Random, 95% Cl 0.02 [0.00, 0.09]	
	Kunst, 2020	1	42	34	40		0.10 [0.01, 0.82]	
		2	42 59	7		15.0%		<u></u>
	Uysal, 2020						0.30 [0.06, 1.48]	
	Deschamps, 2016	4	102	7	99		0.54 [0.15, 1.89]	
	Colak, 2015	9	94	14	96		0.62 [0.25, 1.51]	
	Lei, 2017	30	123	31	126	20.9%	0.99 [0.55, 1.76]	I
	Total (95% CI)		470		477	100.0%	0.28 [0.09, 0.84]	
	Total events	48		101				
	Heterogeneity: Tau ² =	= 1.41; Ch	i ² = 26.63	2, df = 5	(P < 0.0	0001); I ² =	81%	
	Test for overall effect	Z= 2.28	(P = 0.02))				0.01 0.1 1 10 10 Favours [Intervention] Favours [Control]
								Favours (intervention) Favours (Control)
							Odds Ratio	Odds Ratio
	Study or Subgroup	log[O	dds Rati	io]	SE	Weight	IV, Random, 95% Cl	Year IV, Random, 95% CI
	Slater 2009		0.3031	96 0.1	35402	25.6%	1.35 [1.04, 1.77]	2009
	Mohandas 2013		1.7558	75 0.6	27899	9.7%	5.79 [1.69, 19.82]	2013
	Colak 2015		1.0827					
	Deschamps 2016			36 0.1		23.8%		
	Lei 2017		1.0406	02 0.1	96571	23.5%		
	Total (95% CI)					100.0%	2 02 [1 25 3 24]	•
	Total (95% CI) Heterogeneity Tau?	= 0.21· C	'hi² = 21	16 df-	4 (P -	100.0%		
	Heterogeneity: Tau ^a				= 4 (P =			0.05 0.2 1 5 2
					= 4 (P =			
	Heterogeneity: Tau ²	ct: Z = 2.8	9 (P = 0.	.004)			I ² = 81%	0.05 0.2 1 5 2 Favours rSO2 Decrease Favours Control
	Heterogeneity: Tau ^a Test for overall effec	Interver	9 (P = 0.	004) Contr	ol	0.0003);	I ² = 81% Odds Ratio	0.05 0.2 1 5 2 Favours rSO2 Decrease Favours Control Odds Ratio
	Heterogeneity: Tau ² Test for overall effect Study or Subgroup	Interver Events	9 (P = 0. ntion Total	Contr Events	ol Total	0.0003); Weight	I ² = 81 % Odds Ratio M-H, Random, 95% CI	0.05 0.2 1 5 2 Favours rSO2 Decrease Favours Control
	Heterogeneity: Tau ² Test for overall effect <u>Study or Subgroup</u> Colak, 2015	Interver Events 28	9 (P = 0. ntion <u>Total</u> 94	Contr Events 52	ol Total 96	0.0003); <u>Weight</u> 26.0%	Odds Ratio <u>M-H, Random, 95% CI</u> 0.36 [0.20, 0.65]	0.05 0.2 1 5 2 Favours rSO2 Decrease Favours Control Odds Ratio
	Heterogeneity: Tau ² Test for overall effect <u>Study or Subgroup</u> Colak, 2015 Kara, 2015	Interver Events 28 7	9 (P = 0. ntion <u>Total</u> 94 43	Contr Events 52 19	ol <u>Total</u> 96 36	0.0003); Weight 26.0% 20.9%	Odds Ratio <u>M-H, Random, 95% Cl</u> 0.36 [0.20, 0.65] 0.17 [0.06, 0.49]	0.05 0.2 1 5 2 Favours rSO2 Decrease Favours Control Odds Ratio
	Heterogeneity: Tau ² Test for overall effect <u>Study or Subgroup</u> Colak, 2015 Kara, 2015 Lei, 2017	Interver Events 28 7 6	9 (P = 0. 1tion <u>Total</u> 94 43 123	004) Contr Events 52 19 5	ol <u>Total</u> 96 36 126	0.0003); Weight 26.0% 20.9% 19.0%	Odds Ratio <u>M-H, Random, 95% CI</u> 0.36 [0.20, 0.65] 0.17 [0.06, 0.49] 1.24 [0.37, 4.18]	0.05 0.2 1 5 2 Favours rSO2 Decrease Favours Control Odds Ratio
	Heterogeneity: Tau ² Test for overall effect <u>Study or Subgroup</u> Colak, 2015 Kara, 2015	Interver Events 28 7 6 0	9 (P = 0. 1tion <u>Total</u> 94 43 123 50	004) Contr Events 52 19 5 22	ol <u>Total</u> 96 36 126 50	0.0003); Weight 26.0% 20.9%	Odds Ratio <u>M-H, Random, 95% Cl</u> 0.36 [0.20, 0.65] 0.17 [0.06, 0.49]	0.05 0.2 1 5 2 Favours rSO2 Decrease Favours Control Odds Ratio
1.	Heterogeneity: Tau ² Test for overall effect <u>Study or Subgroup</u> Colak, 2015 Kara, 2015 Lei, 2017	Interver Events 28 7 6	9 (P = 0. 1tion <u>Total</u> 94 43 123	004) Contr Events 52 19 5	ol <u>Total</u> 96 36 126	0.0003); Weight 26.0% 20.9% 19.0%	Odds Ratio <u>M-H, Random, 95% CI</u> 0.36 [0.20, 0.65] 0.17 [0.06, 0.49] 1.24 [0.37, 4.18]	0.05 0.2 1 5 2 Favours rSO2 Decrease Favours Control Odds Ratio
	Heterogeneity: Tau ² Test for overall effect Study or Subgroup Colak, 2015 Kara, 2015 Lei, 2017 Mohandas, 2013	Interver Events 28 7 6 0	9 (P = 0. 1tion <u>Total</u> 94 43 123 50	004) Contr Events 52 19 5 22	ol <u>Total</u> 96 36 126 50 115	Weiqht 26.0% 20.9% 19.0% 7.3%	Odds Ratio M-H, Random, 95% CI 0.36 (0.20, 0.65) 0.17 (0.06, 0.49) 1.24 (0.37, 4.18) 0.01 (0.00, 0.21)	0.05 0.2 1 5 2 Favours rSO2 Decrease Favours Control Odds Ratio
	Heterogeneity: Tau ² Test for overall effect Study or Subgroup Colak, 2015 Kara, 2015 Lei, 2017 Mohandas, 2013 Slater, 2009	Interver Events 28 7 6 0	9 (P = 0. Total 94 43 123 50 125	004) Contr Events 52 19 5 22	ol <u>Total</u> 96 36 126 50 115	Weiqht 26.0% 20.9% 19.0% 7.3% 26.8%	Odds Ratio M-H, Random, 95% Cl 0.36 (0.20, 0.65) 0.17 (0.06, 0.49) 1.24 (0.37, 4.18) 0.01 (0.00, 0.21) 0.84 (0.50, 1.41)	0.05 0.2 1 5 2 Favours rSO2 Decrease Favours Control Odds Ratio
	Heterogeneity: Tau ² Test for overall effect Colak, 2015 Kara, 2015 Lei, 2017 Mohandas, 2013 Slater, 2009 Total (95% CI) Total events	Interver <u>Events</u> 28 7 6 0 73 114	9 (P = 0. ntion <u>Total</u> 94 43 123 50 125 435	004) Contr Events 52 19 5 22 72 72	rol <u>Total</u> 96 36 126 50 115 423	Weight 26.0% 20.9% 19.0% 26.8% 100.0%	Odds Ratio <u>M-H, Random, 95% Cl</u> 0.36 (0.20, 0.65) 0.17 (0.06, 0.49) 1.24 (0.37, 4.18) 0.01 (0.00, 0.21) 0.84 (0.50, 1.41) 0.38 [0.16, 0.93]	Olds Ratio M-H, Random, 95% Cl
	Heterogeneity: Tau ² Test for overall effect Colak, 2015 Kara, 2015 Lei, 2017 Mohandas, 2013 Slater, 2009 Total (95% CI) Total events Heterogeneity: Tau ² =	Interver <u>Events</u> 28 7 6 0 73 114 0.69; Chi ²	9 (P = 0. ntion <u>Total</u> 94 43 123 50 125 435 ² = 18.44	004) Contr Events 52 19 5 22 72 72 170 4, df = 4 (rol <u>Total</u> 96 36 126 50 115 423	Weight 26.0% 20.9% 19.0% 26.8% 100.0%	Odds Ratio <u>M-H, Random, 95% Cl</u> 0.36 (0.20, 0.65) 0.17 (0.06, 0.49) 1.24 (0.37, 4.18) 0.01 (0.00, 0.21) 0.84 (0.50, 1.41) 0.38 [0.16, 0.93]	Odds Ratio M-H, Random, 95% Cl 0.01 0.1 1 10 10
	Heterogeneity: Tau ² Test for overall effect Colak, 2015 Kara, 2015 Lei, 2017 Mohandas, 2013 Slater, 2009 Total (95% CI) Total events	Interver <u>Events</u> 28 7 6 0 73 114 0.69; Chi ²	9 (P = 0. ntion <u>Total</u> 94 43 123 50 125 435 ² = 18.44	004) Contr Events 52 19 5 22 72 72 170 4, df = 4 (rol <u>Total</u> 96 36 126 50 115 423	Weight 26.0% 20.9% 19.0% 26.8% 100.0%	Odds Ratio <u>M-H, Random, 95% Cl</u> 0.36 (0.20, 0.65) 0.17 (0.06, 0.49) 1.24 (0.37, 4.18) 0.01 (0.00, 0.21) 0.84 (0.50, 1.41) 0.38 [0.16, 0.93]	Olds Ratio M-H, Random, 95% Cl
	Heterogeneity: Tau ² Test for overall effect Colak, 2015 Kara, 2015 Lei, 2017 Mohandas, 2013 Slater, 2009 Total (95% CI) Total events Heterogeneity: Tau ² =	Interver Events 28 7 6 0 73 114 0.69; Chi	9 (P = 0. ntion <u>Total</u> 94 43 123 50 125 435 ² = 18.44	004) Contr Events 52 19 5 22 72 72 170 4, df = 4 (rol <u>Total</u> 96 36 126 50 115 423	Weight 26.0% 20.9% 19.0% 26.8% 100.0%	Odds Ratio <u>M-H, Random, 95% Cl</u> 0.36 (0.20, 0.65) 0.17 (0.06, 0.49) 1.24 (0.37, 4.18) 0.01 (0.00, 0.21) 0.84 (0.50, 1.41) 0.38 [0.16, 0.93]	Odds Ratio M-H, Random, 95% Cl 0.01 0.1 1 10 10
	Heterogeneity: Tau ² Test for overall effect Colak, 2015 Kara, 2015 Lei, 2017 Mohandas, 2013 Slater, 2009 Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect:	Interver <u>Events</u> 28 7 6 0 73 114 0.69; Chi Z = 2.13 (9 (P = 0. ntion <u>Total</u> 94 43 123 50 125 435 ² = 18.44 P = 0.03)	004) <u>Contre</u> 52 19 5 22 72 170 4, df = 4 (ol <u>Total</u> 96 36 126 50 115 423 (P = 0.0	0.0003); <u>Weight</u> 26.0% 20.9% 19.0% 7.3% 26.8% 100.0% 01); I² = 7	Odds Ratio <u>M-H, Random, 95% Cl</u> 0.36 (0.20, 0.65) 0.17 (0.06, 0.49] 1.24 (0.37, 4.18] 0.01 (0.00, 0.21] 0.84 (0.50, 1.41] 0.38 [0.16, 0.93] 8%	Odds Ratio M-H, Random, 95% Cl 0.01 0.1 1 10 10

Meta-Regression and Subgroup Analyses for the Potential Sources of Heterogeneity

Age, male, body mass index (BMI), previous MI, diabetes mellitus (DM), hypertension, CVA, chronic obstructive pulmonary disease (COPD), chronic renal failure, CPB duration, baseline left ventricular ejection fraction, a European system for cardiac operative risk evaluation, valve surgery, congenital heart disease (CHD) surgery, CABG surgery, and complex surgery were included in the random-effect univariate meta-regression analyses for POD, POCD, and ICU stay. The major sources of heterogeneity were age (coefficient = 0.09; p = 0.03; adjusted $R^2 = 0.99$), BMI (coefficient = 0.53; p = 0.02; adjusted $R^2 = 0.92$) for POD, age (coefficient = 0.13; p = 0.04; adjusted $R^2 = 0.93$) for POCD, DM (coefficient = 0.03; p = 0.07; adjusted $R^2 = 0.65$), CVA (coefficient = 0.11; p = 0.02; adjusted $R^2 = 1$), and COPD

(coefficient = -0.10; p = 0.09; adjusted $R^2 = 1$) for ICU stay as shown in **Table 3**.

Subgroup analyses showed that studies with a mean age of <71.0 years old, a mean BMI of <25.0, and the proportion of CHD surgery being <20.0% had a low risk of POD than those with a mean age of \geq 71.0 years old (OR: 0.22 vs. 0.39, p < 0.01 for a subgroup difference), a mean BMI of \geq 25.0 (OR: 0.02 vs. 0.41, p < 0.001 for a subgroup difference), and the proportion of CHD surgery being \geq 20.0% (OR: 0.02 vs. 0.59, p < 0.001 for a subgroup difference) as shown in **Table 3**.

Studies with a mean age of <63.0 years old had a lower risk of POCD than those with a mean age of \geq 63.0 years old (OR: 0.17 vs. 0.89, *p* < 0.001 for a subgroup difference) as shown in **Table 3**.

Furthermore, patients undergoing the intervention of cerebral oxygen saturation with COPD without DM and CVA had a significantly reduced ICU stay than those without COPD (WMD:

		rventio		-	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean			Mean				IV, Random, 95% CI	IV, Random, 95% CI
Colak, 2015	9.7	4.2	94	9.3	4.1	96	22.3%	0.40 [-0.78, 1.58]	T
Deschamps, 2013		33.6	23	24.9		25		-3.30 [-26.03, 19.43]	
Deschamps, 2016		27.6	102	22.5	6.7	99	4.3%	-5.10 [-10.62, 0.42]	
Lei, 2017	7.8	5.33	123	7.28	6.44	126	20.1%	0.52 [-0.95, 1.99]	Ť
Mohandas, 2013	6.43	2.41	50	7.96	2	50	24.6%	-1.53 [-2.40, -0.66]	
Murkin, 2007	11.4	9.3	100	14.7	23.3	100	5.3%	-3.30 [-8.22, 1.62]	
Uysal, 2020	9.33	4.81	59	8.02	4.07	66	19.4%	1.31 [-0.26, 2.88]	•
Vretzakis, 2013	16.4	24.7	75	14.6	10.3	75	3.7%	1.80 [-4.26, 7.86]	-
Total (95% CI)			626			637	100.0%	-0.27 [-1.52, 0.99]	· · · ·
Heterogeneity: Tau ² =	1.47; CI	hi ² = 1	3.02, df	= 7 (P =	= 0.008	3); I ² = 6	63%		-50 -25 0 25 50
Test for overall effect	Z = 0.42	? (P = 0	.68)						-50 -25 0 25 50 Favours [Intervention] Favours [control]
	Inte	rventio	n	C	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean			Mean		Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Colak, 2015	2.7	6.2	94	1.9	0.9	96	2.6%	0.80 [-0.47, 2.07]	
Deschamps, 2016		2.43	34		3.62	46	2.4%	-0.72 [-2.05, 0.61]	
Kara, 2015		0.81	43		1.05	36	10.8%	-0.38 [-0.80, 0.04]	+
Kunst, 2020	1.6	0.8	42	1.5	0.6	40	13.3%	0.10 [-0.21, 0.41]	+
Lei, 2017	2.04	1.1	123	2.04	1	126	14.3%	0.00 [-0.26, 0.26]	4
Mohandas, 2013		0.39	50	1.7		50	16.1%	-0.20 [-0.37, -0.03]	
Murkin, 2007	1.25		100	1.87	2.67	100	8.5%	-0.62 [-1.17, -0.07]	-
Rogers, 2017	3.01	0.93	98	3.75	0.92	106	14.5%	-0.74 [-0.99, -0.49]	•
Uysal, 2020	3.01	0.5	59	3.75	0.52	66	16.1%	0.00 [-0.18, 0.18]	
Vretzakis, 2013	2.7	3.8	75	2.7	6.6	75	1.5%	0.00 [-1.72, 1.72]	
Total (95% CI)			718			741	100.0%	-0.22 [-0.44, 0.00]	•
Heterogeneity: Tau ² =	= 0.07; C	hi ² = 3	4.12, df	= 9 (P	< 0.00	01); I ² =	74%		
Test for overall effect	Z=1.93	8 (P = 0	.05)						-10 -5 0 5 10 Favours [Intervention] Favours [control]
	Inte	rventio	n	C	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean			Mean		Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Deschamps, 2013	7.6	5.4	23	7.9	3.2	25	5.4%	-0.30 [-2.84, 2.24]	
Deschamps, 2016	11	7.2	34	9.9	5.8	46	4.4%	1.10 [-1.84, 4.04]	
Kara, 2015		1.39	43		1.14	36	15.6%	-0.52 [-1.08, 0.04]	-
Kunst, 2020	8.2	3.2	42	7.4	3.9	40	9.5%	0.80 [-0.75, 2.35]	
Lei, 2017		1.67	123	8	1.67	126	16.3%	0.00 [-0.41, 0.41]	+
Murkin, 2007	6.1	4.4	100	6.9	5.5	100	10.5%	-0.80 [-2.18, 0.58]	
Rogers, 2017		1.33	98	8	1.33	106	16.5%	-1.00 [-1.37, -0.63]	+
Uysal, 2020	6	1.00	59	5	1.00	66	16.5%	1.00 [0.65, 1.35]	+
Vretzakis, 2013	10.9	3.6	75		10.7	75	5.4%	0.70 [-1.85, 3.25]	
Total (95% CI)			597			620	100.0%	-0.02 [-0.73, 0.70]	+
Heterogeneity: Tau ² =	0.78; C	hi² = 6	6.34, df	= 8 (P	< 0.00	001); l²	= 88%		-10 -5 0 5 10
Test for overall effect	Z = 0.05	5 (P = 0	.96)						Favours [Intervention] Favours [control]
								mechanical ventilation	

-0.56 vs. -0.05; p = 0.06 for a subgroup difference), with DM (WMD: -0.72 vs. -0.12; p < 0.001 for a subgroup difference), and CVA (WMD: -0.72 vs. -0.05; p < 0.001 for a subgroup difference) as shown in **Table 3**.

Publication Bias Assessment and Sensitivity Analysis


Table 4 presents the results of publication bias. It was suggested that there was no obvious publication bias in POD (Egger's p = 0.06 and Begg's p = 0.06), POCD (Egger's p = 0.30 and Begg's p = 0.22), rSO₂ desaturation (Egger's p = 0.22 and Begg's p = 0.33), and the length of ICU stay (Egger's p = 0.80 and Begg's p = 0.86).

Trial Sequential Analysis

To confirm the pooled effect sizes of POD, POCD, or ICU stay as the true estimated effect, the required sample sizes for the POD effect are 2,415, the POCD effect is 3,115, and the ICU stay effect is 462. Future trials would need to include approximately further 1,468 POD event rates and 2,257 POCD event rates. However, the sample size of ICU stay (1,459 vs. 462) is enough for the estimated effect.

DISCUSSION

The present meta-analysis suggested that cerebral oximetry monitoring-guided intraoperative intervention was associated



(C) surgical site infection, (D) cerebrovascular accident (CVA), and (E) hospital mortality.

Variables	Endpoint	No. of comparisons	Coeff./OR/WMD WMD	95% CI	P-value		
Univariate			Coeff.				Adjusted R ²
Age (years)	POD (Ln)	6	0.09	0.02 ~ 016	0.03		0.99
	POCD (Ln)	5	0.13	$0.01 \sim 0.26$	0.04		0.93
BMI	POD (Ln)	4	0.53	$-0.01 \sim 1.07$	0.05		0.97
CHD (%)	POD (Ln)	6	-0.17	$-0.30\sim-0.04$	0.02		0.92
DM (%)	ICU stay	7	0.03	$-0.003 \sim 0.07$	0.07		0.65
CVA (%)	ICU stay	5	0.11	$0.04 \sim 0.18$	0.02		1.00
COPD (%)	ICU stay	5	-0.10	$-0.23 \sim 0.31$	0.09		1.00
Subgroup						l ²	P _{Difference} value
			OR				
1. Age (years)	POD	6					0.01
≥71.0		2	0.39	$0.04 \sim 3.74$	0.42	77.1%	
<71.0		4	0.22	$0.05 \sim 1.00$	0.05	81.50%	
2. Age (years)	POCD	5					0.001
≥63.0		2	0.89	$0.55 \sim 1.44$	0.64	0.00%	
<63.0		3	0.17	$0.05 \sim 0.59$	0.01	70.8%	
3.BMI	POD	4					< 0.001
≥25.0		3	0.41	$0.10 \sim 1.59$	0.20	65.7%	
<25.0		1	0.02	$0.004 \sim 0.09$	< 0.001	%	
4. CHD	POD	6					< 0.001
≥20.0%		5	0.59	$0.32 \sim 1.07$	0.08	34.3%	
<20.0%		1	0.02	$0.004 \sim 0.09$	< 0.001	%	
			WMD				
5. DM	ICU stay	7					< 0.001
≥25.0%		5	-0.12	$-0.41 \sim 0.17$	0.42	56.7%	
<25.0%		2	-0.72	$-0.98\sim-0.47$	< 0.001	0.0%	
6. CVA	ICU stay	5					< 0.001
≥10.0%		3	-0.05	$-0.30 \sim 0.19$	0.66	41.4%	
<10.0%		2	-0.72	$-0.95\sim-0.99$	< 0.001	0.0%	
7. COPD	ICU stay	5					0.06
≥16.0%		2	-0.56	$-1.09 \sim -0.04$	0.04	0.0%	
<16.0%		3	-0.05	$-0.30 \sim -0.19$	0.66	41.4%	

TABLE 3 | Meta-regression and subgroup analyses for the potential sources of heterogeneity.

POD, postoperative delirium; POCD, postoperative cognitive decline; ICU stay, intensive care unit stay; BMI, body mass index; CHD, congenital heart disease; DM, diabetes mellitus; CVA, cardiovascular accident; COPD, chronic obstructive pulmonary disease; Coeff., coefficient; OR, odds ratio; WMD, weighted mean difference; CI, confidence Interval.

with a lower risk of POD and POCD and a shorter ICU stay in adults undergoing cardiac surgery. Similarly, we found an increased occurrence of POD with cerebral oximetry desaturation defined by both relative (below 70–90% baseline rSO_2) or absolute (below 50–60% absolute rSO_2) thresholds. These clinical benefits may be limited in patients with older age, diabetes status, high BMI, non-CHD, non-COPD, or a previous CVA.

In our study, the incidences of POD and POCD in 846 and 858 patients undergoing on-pump cardiac surgery were evaluated, of whom 149 (18.0%) and 284 (31.1%) were, respectively, diagnosed positive. POD is a common complication with a rate of 3.1–52% of adult patients undergoing cardiac surgery when defined as a disorder with an acute disturbance in attention and cognition (33). There are many factors associated with an increased risk of delirium, including advancing age, baseline cognitive impairment, preoperative comorbid conditions, and the type of surgery (34). Severe inflammatory responses, hypoperfusion and embolism related to CPB, are proposed to influence the cerebral oxygen supply/demand balance, and they cause subsequent delirium in a cardiac surgery patient (8). Greaves et al. did a metaanalysis to estimate the prevalence of cognitive impairments pre- and post-CABG, including delirium and dementia. They identified 215 studies with 91,829 patients and demonstrated that postoperative cognitive impairment increases to about 40% of patients acutely and then increases to nearly 40% in the longterm period (35). Their research findings provided important

Index	OR (95% CI)	Ζ	P-value	l ² (%)	l²'s P	Egger's P	Begg's P
POD	0.29 (0.10, 0.89)	2.16	0.03	81	<0.001	0.06	0.06
POCD	0.38 (0.16, 0.93)	2.13	0.03	78	=0.001	0.30	0.22
rSO ₂ desaturation	2.02 (1.25, 3.24)	2.89	0.004	81	< 0.001	0.22	0.33
ICU stay	-0.22 (-0.44, 0.00)	1.93	0.05	74	<0.001	0.80	0.86

TABLE 4 | Evaluation of publication bias and sensitivity analysis.

OR, odd ratio; 95% CI, 95% confidence interval; POD, postoperative delirium; POCD, postoperative cognitive decline; rSO2, regional cerebral oxygen saturation; ICU, intensive care unit.

warnings about a cognitive decline in elderly patients, and more attention needs to be focused on the long-term (1-5 years) prognosis.

A multicenter observational study found that the prevalence of one or more rSO₂ desaturations was 50-70% in cardiac surgery with CPB (36), prolonged rSO₂ desaturation, and severe rSO₂ desaturation significantly increased the risk of postoperative neurologic impairment (37, 38). In an observational study of 1,439 patients who underwent offpump CABG surgery, intraoperative rSO₂ reduction was associated with an increased risk of POD. The duration of $rSO_2 < 50\%$ was 40% longer in patients with POD. For the prediction of POD, the cut-off value of intraoperative rSO₂ was 50% for the total patient population, and 55% for patients younger than 68 years (39). Cournoyer et al. included 20 non-randomized studies in patients after cardiac arrest and concluded that a higher regional cerebral saturation is associated with improved resuscitation outcomes, especially the return to spontaneous circulation (40). In our meta-analysis, there is an increased occurrence of POD with cerebral oximetry desaturation defined by both relative (below 70-90% baseline rSO₂) or absolute (below 50-60% absolute rSO₂) thresholds. The results in this study are consistent with a previous report that suggested an association between cerebral oximetry desaturation with postoperative neurological impairment after cardiac surgery.

Determining whether the clinical benefits of rSO₂ monitoring may interfere with patient characteristics in adult cardiac surgery has been an intriguing issue for a long time. Our analysis found that cerebral oximetry monitoring-guided intraoperative interventions had a low risk of POD in younger patients (<71.0 years old) and a lower BMI (<25.0), a significant reduction of POCD in patients with a mean age of <63.0 years old compared with control. Ding et al. conducted a metaanalysis and found that the intraoperative cerebral oxygenation monitoring could decrease the risk of POCD but have no effect on POD in non-cardiac and cardiac surgeries (41). Our metaregression analysis showed that age was negatively correlated with the reduction in POD and POCD in the intervention group. In addition, we also found that the lengths of ICU stay were less in the intervention group with a marginal statistical significance. This result was similar to that reported by Zorrilla-Vaca et al., 1,300 patients from 9 RCTs in both cardiac and non-cardiac surgeries were analyzed with a higher heterogeneity (42). Subgroup analyses showed that patients with COPD, non-DM, and non-CVA had a significantly reduced ICU stay compared with the control. Cognitive dysfunction after cardiac surgery has been reported to be in association with an increased hospital stay, a prolonged ICU stay, a long-term cognitive dysfunction, and an increased risk for short-term mortality (2). Based on the findings from our study, determining whether pre-selecting a certain cohort of patients with a high risk of cognitive dysfunction may more likely show a significant decrease in the risks of POD and POCD by cerebral oximetry monitoring-guided interventions and eventually improve clinical outcomes, remains to be assessed in future, powered multicenter RCTs.

The major strength of our study includes gathering the largest sample size with only cardiac surgery, obtaining the positive effect of intervention based on cerebral SO₂ monitoring on POD/POCD/ICU stay, and conducting a comprehensive exploration of clinically relevant influential factors (age, diabetes, BMI, and a previous CVA). However, this meta-analysis has several limitations. First, there are multiple mechanisms to develop POD and POCD, namely embolism, inflammation, and hypoperfusion, and they may not have the same risk factors. Hence, the potential interference of patient characteristics (age, diabetes, and peripheral vascular disease), cardiovascular medications, hemodynamic instability, and CPB duration may be underestimated. Second, the definitions for cerebral desaturation are different among the included trials. Third, non-English language publications were excluded and may result in a potential publication bias. However, the publication bias assessments were not obvious. Finally, the included research were all RCTs with comparatively small sample size, only 7 RCTs qualified for the meta-regression analysis, and therefore, the conclusions may not be robust but hypothesis generating. To clarify the neuroprotection effectiveness of intraoperative interventions followed by optimizing cerebral oxygenation in cardiac surgical patients, further large randomized trials are needed.

In conclusion, the available evidence in the metaanalysis suggests that cerebral oximetry monitoring-guided intraoperative interventions are correlated with a lower risk of postoperative cognitive dysfunction and a shorter ICU stay in adults undergoing cardiac surgery. These clinical benefits may be limited in patients with older age, diabetes status, high BMI, non-CHD, non-COPD, or a previous cardiovascular accident. Based on the fact that an intraoperative intervention followed cerebral oxygenation may provide significant benefits in patients with a high-risk status, and further trials are needed to verify the effectiveness of cerebral oxygen saturation intervention threshold settings in improving cognitive function.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.

REFERENCES

- 1. Rengel KF, Pandharipande PP, Hughes CG. Postoperative delirium. Presse Med. (2018) 47:e53–64. doi: 10.1016/j.lpm.2018.03.012
- Inouye SK, Westendorp RG, Saczynski JS. Delirium in elderly people. *Lancet.* (2014) 383:911–22. doi: 10.1016/S0140-6736(13)60688-1
- Koster S, Hensens AG, Schuurmans MJ, van der Palen J. Risk factors of delirium after cardiac surgery: a systematic review. *Eur J Cardiovasc Nurs.* (2011) 10:197–204. doi: 10.1016/j.ejcnurse.2010.09.001
- Kazmierski J, Kowman M, Banach M, Fendler W, Okonski P, Banys A, et al. Incidence and predictors of delirium after cardiac surgery: results from the IPDACS study. J Psychosom Res. (2010) 69:179– 85. doi: 10.1016/j.jpsychores.2010.02.009
- Ely EW, Shintani A, Truman B, Speroff T, Gordon SM, Harrell FE Jr, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. J Am Med Assoc. (2004) 291:1753– 62. doi: 10.1001/jama.291.14.1753
- Jackson JC, Gordon SM, Hart RP, Hopkins RO, Ely EW. The association between delirium and cognitive decline: a review of the empirical literature. *Neuropsychol Rev.* (2004) 14:87–98. doi: 10.1023/B:NERV.0000028080.39602.17
- Vasilevskis EE, Chandrasekhar R, Holtze CH, Graves J, Speroff T, Girard TD, et al. The cost of ICU delirium and coma in the intensive care unit patient. *Med Care*. (2018) 56:890–7. doi: 10.1097/MLR.000000000000975
- Gosselt AN, Slooter AJ, Boere PR, Zaal IJ. Risk factors for delirium after on-pump cardiac surgery: a systematic review. *Crit care.* (2015) 19:346. doi: 10.1186/s13054-015-1060-0
- Lopez MG, Pandharipande P, Morse J, Shotwell MS, Milne GL, Pretorius M, et al. Intraoperative cerebral oxygenation, oxidative injury, and delirium following cardiac surgery. *Free Radic Biol Med.* (2017) 103:192– 8. doi: 10.1016/j.freeradbiomed.2016.12.039
- Murkin JM. Cerebral oximetry: monitoring the brain as the index organ. Anesthesiology. (2011) 114:12–3. doi: 10.1097/ALN.0b013e3181fef5d2
- Yu Y, Zhang K, Zhang L, Zong H, Meng L, Han R. Cerebral nearinfrared spectroscopy (NIRS) for perioperative monitoring of brain oxygenation in children and adults. *Cochrane Database Syst Rev.* (2018) 1:Cd010947. doi: 10.1002/14651858.CD010947.pub2
- Scheeren TW, Schober P, Schwarte LA. Monitoring tissue oxygenation by near infrared spectroscopy (NIRS): background and current applications. J Clin Monit Comput. (2012) 26:279–87. doi: 10.1007/s10877-012-9348-y
- Jo YY, Shim JK, Soh S, Suh S, Kwak YL. Association between cerebral oxygen saturation with outcome in cardiac surgery: brain as an index organ. J Clin Med. (2020) 9:840. doi: 10.3390/jcm9030840
- Momeni M, Meyer S, Docquier MA, Lemaire G, Kahn D, Khalifa C, et al. Predicting postoperative delirium and postoperative cognitive decline with combined intraoperative electroencephalogram monitoring and cerebral near-infrared spectroscopy in patients undergoing cardiac interventions. J Clin Monit Comput. (2019) 33:999–1009. doi: 10.1007/s10877-019-00253-8
- Wildes TS, Mickle AM, Ben Abdallah A, Maybrier HR, Oberhaus J, Budelier TP, et al. Effect of electroencephalography-guided anesthetic administration on postoperative delirium among older adults undergoing major surgery: the ENGAGES randomized clinical trial. *J Am Med Assoc.* (2019) 321:473– 83. doi: 10.1001/jama.2018.22005

AUTHOR CONTRIBUTIONS

L-JT and C-HZ made a substantial contribution to the conception and design of the work and manuscript drafting. L-JT, SY, C-HZ, and F-XY contributed to the acquisition, analysis, and interpretation of the data. All authors were involved in drafting and revision of the manuscript for important intellectual content and approved the final version to be published.

- Uysal S, Lin HM, Trinh M, Park CH, Reich DL. Optimizing cerebral oxygenation in cardiac surgery: A randomized controlled trial examining neurocognitive and perioperative outcomes. J Thorac Cardiovasc Surg. (2020) 159:943–53. doi: 10.1016/j.jtcvs.2019.03.036
- Deschamps A, Hall R, Grocott H, Mazer CD, Choi PT, Turgeon AF, et al. Cerebral oximetry monitoring to maintain normal cerebral oxygen saturation during high-risk cardiac surgery: a randomized controlled feasibility trial. *Anesthesiology*. (2016) 124:826–36. doi: 10.1097/ALN.000000000001029
- Lei L, Katznelson R, Fedorko L, Carroll J, Poonawala H, Machina M, et al. Cerebral oximetry and postoperative delirium after cardiac surgery: a randomised, controlled trial. *Anaesthesia*. (2017) 72:1456–66. doi: 10.1111/anae.14056
- Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.2. Cochrane; 2021. Available online at: https://training.cochrane.org/handbook/current (accessed October 22, 2021).
- Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. Cochrane Statistical Methods Group the Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ.* (2011) 343:d5928. doi: 10.1136/bmj.d5928
- Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med Res Methodol.* (2014) 14:135. doi: 10.1186/1471-2288-14-135
- Schmid CH, Stark PC, Berlin JA, Landais P, Lau J. Meta-regression detected associations between heterogeneous treatment effects and studylevel, but not patient-level, factors. J Clin Epidemiol. (2004) 57:683– 97. doi: 10.1016/j.jclinepi.2003.12.001
- Egger M, Davey Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. *BMJ.* (1997) 315:629– 34. doi: 10.1136/bmj.315.7109.629
- Murkin JM, Adams SJ, Novick RJ, Quantz M, Bainbridge D, Iglesias I, et al. Monitoring brain oxygen saturation during coronary bypass surgery: a randomized, prospective study. *Anesth Analg.* (2007) 104:51– 8. doi: 10.1213/01.ane.0000246814.29362.f4
- Slater JP, Guarino T, Stack J, Vinod K, Bustami RT, Brown JM 3rd, et al. Cerebral oxygen desaturation predicts cognitive decline and longer hospital stay after cardiac surgery. *Ann Thoracic Surg.* (2009) 87:36– 44. doi: 10.1016/j.athoracsur.2008.08.070
- 26. Vretzakis G, Georgopoulou S, Stamoulis K, Tassoudis V, Mikroulis D, Giannoukas A, et al. Monitoring of brain oxygen saturation (INVOS) in a protocol to direct blood transfusions during cardiac surgery: a prospective randomized clinical trial. *J Cardiothorac Surg.* (2013) 8:145. doi: 10.1186/1749-8090-8-145
- Deschamps A, Lambert J, Couture P, Rochon A, Lebon JS, Ayoub C, et al. Reversal of decreases in cerebral saturation in high-risk cardiac surgery. J Cardiothorac Vasc Anesth. (2013) 27:1260–6. doi: 10.1053/j.jvca.2013.01.019
- Mohandas BS, Jagadeesh AM, Vikram SB. Impact of monitoring cerebral oxygen saturation on the outcome of patients undergoing open heart surgery. *Ann Card Anaesth.* (2013) 16:102–6. doi: 10.4103/0971-9784.109740
- Colak Z, Borojevic M, Bogovic A, Ivancan V, Biocina B, Majeric-Kogler V. Influence of intraoperative cerebral oximetry monitoring on neurocognitive function after coronary artery bypass surgery: a randomized, prospective study. *Eur J Cardio-Thoracic Surg.* (2015) 47:447–54. doi: 10.1093/ejcts/ezu193

- 30. Kara I, Erkin A, Sacli H, Demirtas M, Percin B, Diler MS, et al. The effects of near-infrared spectroscopy on the neurocognitive functions in the patients undergoing coronary artery bypass grafting with asymptomatic carotid artery disease: a randomized prospective study. *Ann Thoracic Cardiovasc Surg.* (2015) 21:544–50. doi: 10.5761/atcs.oa.15-00118
- Rogers CA, Stoica S, Ellis L, Stokes EA, Wordsworth S, Dabner L, et al. Randomized trial of near-infrared spectroscopy for personalized optimization of cerebral tissue oxygenation during cardiac surgery. *Br J Anaesth.* (2017) 119:384–93. doi: 10.1093/bja/aex182
- 32. Kunst G, Gauge N, Salaunkey K, Spazzapan M, Amoako D, Ferreira N, et al. Intraoperative optimization of both depth of anesthesia and cerebral oxygenation in elderly patients undergoing coronary artery bypass graft surgery-a randomized controlled pilot trial. *J Cardiothorac Vasc Anesth.* (2020) 34:1172–81. doi: 10.1053/j.jvca.2019.10.054
- Neufeld KJ, Leoutsakos JM, Sieber FE, Wana-maker BL, Gibson Chambers JJ, Rao V, et al. Outcomes of early delirium diagnosis after general anesthesia in the elderly. *Anesth Analg.* (2013) 117:471–8. doi: 10.1213/ANE.0b013e3182973650
- Hughes CG, Patel MB, Jackson JC, Girard TD, Geevarghese SK, Norman BC, et al. Surgery and anesthesia exposure is not a risk factor for cognitive impairment after major noncardiac surgery and critical illness. *Ann Surg.* (2017) 265:1126–33. doi: 10.1097/SLA.000000000001885
- Greaves D, Psaltis PJ, Ross TJ, Davis D, Smith AE, Boord MS, et al. Cognitive outcomes following coronary artery bypass grafting: a systematic review and meta-analysis of 91,829 patients. *Int J Cardiol.* (2019) 289:43– 9. doi: 10.1016/j.ijcard.2019.04.065
- 36. Subramanian B, Nyman C, Fritock M, Klinger RY, Sniecinski R, Roman P, et al. A multicenter pilot study assessing regional cerebral oxygen desaturation frequency during cardiopulmonary bypass and responsiveness to an intervention algorithm. *Anesth Analg.* (2016) 122:1786–93. doi: 10.1213/ANE.00000000001275
- Heringlake M, Garbers C, Käbler JH, Anderson I, Heinze H, Schön J, et al. Preoperative cerebral oxygen saturation and clinical outcomes in cardiac surgery. *Anesthesiology.* (2011) 114:58–69. doi: 10.1097/ALN.0b013e3181fef34e
- Green DW, Kunst G. Cerebral oximetry and its role in adult cardiac, noncardiac surgery and resuscitation from cardiac arrest. *Anaesthesia*. (2017) 72(Suppl.1):48–57. doi: 10.1111/anae.13740

- 39. Lim L, Nam K, Lee S, Cho YJ, Yeom CW, Jung S, et al. The relationship between intraoperative cerebral oximetry and postoperative delirium in patients undergoing off-pump coronary artery bypass graft surgery: a retrospective study. *BMC Anesthesiol.* (2020) 20:285. doi: 10.1186/s12871-020-01180-x
- Cournoyer A, Iseppon M, Chauny JM, Denault A, Cossette S, Notebaert E. Near-infrared spectroscopy monitoring during cardiac arrest: a systematic review and meta-analysis. *Acad Emerg Med.* (2016) 23:851–62. doi: 10.1111/acem.12980
- Ding L, Chen DX, Li Q. Effects of electroencephalography and regional cerebral oxygen saturation monitoring on perioperative neurocognitive disorders: a systematic review and meta-analysis. *BMC Anesthesiol.* (2020) 20:254. doi: 10.1186/s12871-020-0 1163-y
- Zorrilla-Vaca A, Healy R, Grant MC, Joshi B, Rivera-Lara L, Brown C, et al. Intraoperative cerebral oximetry-based management for optimizing perioperative outcomes: a meta-analysis of randomized controlled trials. *Can J Anaesth.* (2018) 65:529–42. doi: 10.1007/s12630-018-1065-7

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Tian, Yuan, Zhou and Yan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.